Dendritic Cell p53 Immunotherapy for SCLC Survival
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for small cell lung cancer (SCLC) are limited, with first-line therapies providing short-term survival benefits but rarely extending beyond two years, and second-line therapies showing disappointing overall response rates, especially in platinum-resistant cases.
Innovation Solution
Administering therapeutically effective amounts of dendritic cells engineered to overexpress p53, combined with all-trans-retinoic acid (ATRA) and immune checkpoint inhibitors, such as anti-PD-1 or anti-CTLA-4 antibodies, to stimulate an immune response against tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy is used as first-line treatment for ES-SCLC, then overall response rate is improved (≥70%), but median survival time remains limited (7-10 months)
Solution Approach 1:
The patent combines multiple therapeutic modalities into a unified treatment regimen: dendritic cell vaccination (Ad-p53-DC), all-trans-retinoic acid (ATRA) treatment, and immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies). This combination approach integrates antigen presentation enhancement, immune modulation, and checkpoint blockade to achieve both high response rates and prolonged survival in ES-SCLC patients
Solution Approach 2:
The patent employs preliminary action by administering ATRA before dendritic cell vaccination to pre-condition the immune environment. ATRA treatment depletes immunosuppressive myeloid-derived suppressor cells (MDSCs) and enhances dendritic cell maturation and antigen presentation capacity, thereby preparing the immune system for more effective anti-tumor response when the vaccine is administered
2Adaptability or versatility
If second-line chemotherapy is administered to platinum-resistant patients, then treatment options are provided, but overall response rate is very disappointing (≤10%)
Solution Approach 1:
The patent fundamentally changes the therapeutic parameter from conventional chemotherapy to immunotherapy-based combination treatment. By shifting from cytotoxic agents to dendritic cell vaccination combined with immune checkpoint inhibitors, the treatment mechanism changes from direct cell killing to immune-mediated tumor destruction, achieving meaningful response rates in platinum-resistant patients where chemotherapy has failed
3Duration of action of moving object
If dendritic cells are engineered to overexpress p53 and combined with ATRA and immune checkpoint inhibitors, then immune response and survival rates are improved, but treatment complexity increases
Solution Approach 1:
The patent segments the complex immunotherapy regimen into distinct, sequentially administered components: (1) ATRA oral administration for immune environment conditioning, (2) Ad-p53-DC intradermal vaccination for antigen-specific immune priming, and (3) immune checkpoint inhibitor intravenous infusion for checkpoint blockade. This segmentation allows each component to be optimized independently and administered by different specialists, managing overall treatment complexity
Data Source
AI summary
A method is disclosed for treating small cell lung cancer (SCLC) in a subject that involves administering to the subject a therapeutically effective amount of dendritic cells engineered to overexpress p53. In some embodiments, the method further involves administering to the subject a therapeutically effective amount of all-trans-retinoic acid (ATRA). The method can also involve administering to the subject a therapeutically effective amount of an immune checkpoint inhibitor.